Applications

1174 – Pathology test to determine if a patient has been infected with CCR5 tropic HIV-1 for access to maraviroc

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type New application
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome Not supported

Application details

Reason for application

-

Service or technology in this application

A proposal was received seeking genotypic HIV tropism testing to be funded through two avenues: 

  1. Through the creation of a new MBS item number to allow HIV tropism testing as part of the current genotype-assisted antiretroviral resistance testing suite of tests; and
  2. through the creation of a new MBS item number for HIV tropism testing alone.

HIV tropism testing is a co-dependent technology to determine eligibility for access to maraviroc. 

Medical condition this application addresses

HIV is a viral infection that causes immunosuppression. If untreated this leads to a number of different opportunistic infections and diseases that are called Acquired Immune Deficiency Syndrome (AIDS). AIDS diseases are often life-threatening and prior to the introduction of effective antiretroviral therapies, patients with AIDS had a prognosis of around two years. The treatment of HIV-1 is complex, with the choice to treat and choice of treatment highly individualised. Treatment decisions depend on virologic efficacy, drug-drug interaction potential, resistance testing results, and co-morbid conditions.

Meetings to consider this application

  • PASC meeting: 
    • 14 - 15 September 2011
    • 1 - 2 December 2011
  • ESC meeting: 
    • 11 - 12 October 2012
  • MSAC meeting: 
    • 29 - 30 November 2012

More information

Note: the assessment report submission has been withheld at the request of the applicant.